Novartis to Buy Fougera for $1.5 Billion for Skin Drugs

Novartis AG, Europe’s largest drugmaker, said it will spend $1.5 billion for closely held Fougera Pharmaceuticals Inc. in a deal to become the top seller of generic skin medications.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.